No abstract

Aspergillosis is a common respiratory fungal disease in penguins managed under human care. Triazole antifungal drugs, including itraconazole, are most commonly used for treatment; however, itraconazole treatment failures from drug resistance are becoming more common, requiring newer treatment options. Voriconazole, a newer triazole, is being used more often. Until recently, no voriconazole pharmacokinetic studies had been performed in penguins, leading to empiric dosing based on other avian studies. This has led to increased anecdotal reporting of apparent voriconazole toxicity in penguins. This report describes 18 probable and 6 suspected cases of voriconazole toxicity in six penguin species from nine institutions: 12 African penguins (Spheniscus demersus), 5 Humboldt penguins (Spheniscus humboldti), 3 Magellanic penguins (Spheniscus magellanicus), 2 gentoo penguins (Pygoscelis papua papua), 1 macaroni penguin (Eudyptes chrysolophus), and 1 emperor penguin (Aptenodytes forsteri). Observed clinical signs of toxicity included anorexia, lethargy, weakness, ataxia, paresis, apparent vision changes, seizure-like activity, and generalized seizures. Similar signs of toxicity have also been reported in humans, in whom voriconazole therapeutic plasma concentration for Aspergillus spp. infections is 2-6 μg/ml. Plasma voriconazole concentrations were measured in 18 samples from penguins showing clinical signs suggestive of voriconazole toxicity. The concentrations ranged from 8.12 to 64.17 μg/ml, with penguins having plasma concentrations above 30 μg/ml exhibiting moderate to severe neurologic signs, including ataxia, paresis, and seizures. These concentrations were well above those known to result in central nervous system toxicity, including encephalopathy, in humans. This case series highlights the importance of species-specific dosing of voriconazole in penguins and plasma therapeutic drug monitoring. Further investigation, including pharmacokinetic studies, is warranted. The authors recommend caution in determining voriconazole dosages for use in penguin species.

Circumvitellatrema momota n. gen., n. sp. was found in the air sacs of a captive-hatched blue-crowned motmot, Momotus momota (Momotidae), that was being maintained in quarantine at the Animal Health Center of the Philadelphia Zoo in Philadelphia, Pennsylvania, U.S.A. This bird apparently became infected at the Audubon Zoo, New Orleans, Louisiana, U.S.A. where it was maintained for several years prior to being sent to the Philadelphia Zoo. In the new genus, the ovary is intertesticular, forming a triangle with the testes and the genus is assigned to Cyclocoelinae. It can be distinguished from the other 3 genera currently assigned to this subfamily (Cyclocoelum, Psophiatrema, and Selfcoelum) by having the vitelline fields confluent at both the anterior and posterior ends of the body forming a continuous loop. This new species was likely introduced into the Audubon Zoo through the importation of species of exotic birds.

No abstract

No abstract

No abstract

No abstract

This communication reports a partially reversible chemical immobilization protocol used for translocation and veterinary care in giant otter (Pteronura brasiliensis; GO). Six GOs (three males and three females) weighing 24.8 +/- 4.0 kg (mean +/- SD) and ranging in age from 16 to 42 mo old were anesthetized with an i.m. combination of medetomidine (29 +/- 3 microg/kg) and ketamine (3.9 +/- 0.4 mg/kg). To perform all procedures, two otters required an additional dose of ketamine (1.5 mg/kg). Anesthesia was reversed with atipamezole i.m. (147 +/- 14 mg/kg). The mean induction time and recovery times were 12 +/- 5 and 4 min (range, 0-9 min), respectively, with an anesthesia time of 47 +/- 16 min. According to these results, the combination of medetomidine (30 microg/kg i.m.) and ketamine (4 mg/kg i.m.) is a reasonable choice for inducing anesthesia in GOs.